Reply to Fiser et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.

Majeti, Ravindra; Dove, Christopher; McClellan, James Scott

Majeti, Ravindra; Dove, Christopher; McClellan, James Scott.

Afiliação

Majeti R; Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305 rmajeti@stanford.edu.
Dove C; Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.
McClellan JS; Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.

Proc Natl Acad Sci U S A ; 112(27): E3456, 2015 Jul 07.

Article em En | MEDLINE | ID: mdl-26069209

Assuntos

Linfócitos B/metabolismo; Macrófagos/citologia; Cromossomo Filadélfia; Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética; Leucemia-Linfoma Linfoblástico de Células Precursoras B/metabolismo; Animais; Feminino; Humanos; Masculino

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cromossomo Filadélfia / Linfócitos B / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Macrófagos Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google